The Top 5 Biosimilars Articles for the Week of September 16
The Center for Biosimilars® recaps the top stories for the week of September 16, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 16, 2019.
Number 5: Innovator drug maker Roche says that it plans to see substantial erosion of its sales of rituximab, trastuzumab, and bevacizumab products by 2023.
Number 4: The American College of Rheumatology says that a large proportion of patients with rheumatic diseases had difficulty accessing and paying for their therapies in the past year.
Number 3: The Biosimilars Council has issued part 2 of its recent white paper on barriers to biosimilars in the United States; the newly published segment highlights post-market challenges to biosimilar adoption.
Number 2: A recent study says that step therapy in rheumatoid arthritis or psoriatic arthritis can hurt treatment outcomes.
Number 1: The United States Court of Appeals for the Third Circuit sided with Johnson & Johnson, requiring a dispute between the drug maker and Rochester Drug Cooperative to be sent to arbitration.
Finally, last week, our e-newsletter asked whether you think that Europe’s biosimilars market faces challenges to sustainability.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
